🧬 The AVATAR™ Foundry system will enable rapid production of tumor-infiltrating lymphocytes for trials.
💡 This innovation promises to reduce manufacturing time and enhance cell potency, addressing current inefficiencies.
👩⚕️ The collaboration aims to improve cancer treatment options for patients in Australia and globally.
Introduction:
The collaboration between Xcell Biosciences Australia and Royal Perth Hospital aims to revolutionize the manufacturing process of tumor-infiltrating lymphocyte (TIL) therapies utilizing the advanced AVATAR™ Foundry system. This partnership focuses on enhancing the efficiency and efficacy of TIL-based immunotherapies, which hold significant promise in the treatment of various solid tumors.
- Xcell Biosciences and Royal Perth Hospital are collaborating to develop an automated workflow for TIL therapy manufacturing using the AVATAR™ Foundry system.
- TIL therapies are an emerging class of immunotherapies with the potential to treat a broad array of solid tumors, following recent FDA approvals.
- The current manual manufacturing process for TIL therapies is slow and labor-intensive, taking weeks to produce the necessary therapeutic doses.
- The AVATAR platform enhances TIL metabolic fitness, reducing manufacturing times and improving cell potency.
- The automation of the manufacturing process seeks to support clinical trials, ultimately making TIL therapies more accessible for patients in Australia and globally.
Conclusion:
This collaboration between Xcell Biosciences and Royal Perth Hospital is set to significantly streamline the production of TIL therapies, addressing existing manufacturing challenges. By harnessing innovative technology, the project not only promises to enhance therapeutic application efficacy but also significantly improve the accessibility and feasibility of these treatments for cancer patients in the near future.
